화상 통증 : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Burn Pain Market Outlook

Thelansis's "Burn Pain Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Burn Pain treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Burn Pain Overview

Burn pain is a uniquely severe, complex, and dynamic neuroinflammatory condition characterized by the coexistence of intense nociceptive input from tissue destruction and neuropathic signaling from damaged nerve endings. The pathophysiology is driven by profound inflammatory cascades, resulting in peripheral sensitization (primary hyperalgesia) and sustained central nervous system sensitization (secondary hyperalgesia).

Clinically, burn pain is highly heterogeneous and requires clear stratification into:

1. Background pain (persistent, inflammatory)

2. Breakthrough pain (episodic exacerbations)

3. Procedural pain (severe pain during wound care, debridement, and grafting)

Inadequate acute pain control is strongly associated with long-term complications, including chronic neuropathic pain and post-traumatic stress disorder (PTSD), making early and effective intervention critical.

The modern treatment paradigm has shifted away from opioid monotherapy toward a multimodal analgesic approach, incorporating:

• Opioids for acute and procedural pain
• NSAIDs and acetaminophen for inflammatory control
• Gabapentinoids for neuropathic modulation
• NMDA receptor antagonists (e.g., ketamine) for severe pain and opioid-sparing effects

Advanced burn care increasingly integrates:

• Regional anesthesia techniques
• Alpha-2 agonists (e.g., dexmedetomidine) for sedation and anxiolysis
• Non-pharmacological interventions, such as virtual reality (VR)-based distraction therapy, to address psychological burden

This multimodal, patient-centric approach reflects the need to manage both the physiological and psychological dimensions of burn pain.

Key Highlights

• Burn pain represents a high-intensity, procedure-driven therapeutic area, where treatment demand is closely linked to incidence rather than prevalence.
• In Italy, the annual burn incidence population is expected to grow modestly (1% CAGR), increasing from 188K to 204K cases, reflecting stable but persistent disease burden.

Market Overview

• The burn pain market in Germany is projected to grow from $65M to $125M by 2035, reflecting a robust CAGR of 6-7%
• The burn patient population shows low but steady growth (~1% CAGR) in Italy

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Shanghai Bao Pharmaceuticals Co.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)